| Business Summary | | Hemispherx
BioPharma,
Inc.
is
a
pharmaceutical
research
and
development
company
using
nucleic
acid
technologies
to
develop
therapeutic
products
for
the
treatment
of
certain
viral
diseases
and
cancers.
The
Company's
proprietary
drug
technology
utilizes
specifically
configured
ribonucleic
acid
(RNA).
Hemishperx
has
established
a
base
of
laboratory,
pre-clinical
and
clinical
data
to
support
the
commercialization
of
its
lead
compound,
Ampligen,
for
use
in
treating
immune
system
dysfunction,
viral
diseases
and
certain
cancers.
Ampligen
is
undergoing
Phase
II/III
clinical
trials
in
the
United
States
and
Europe
for
the
treatment
of
Myalgic
Encephalomyelitis/Chronic
Fatigue
syndrome.
The
Company's
three
domestic
subsidiaries
include
BioPro
Corp.,
BioAegean
Corp.
and
Core
BioTech
Corp.
Its
foreign
subsidiary,
Hemispherx
BioPharma
Europe,
N.V./S.A.,
was
established
in
1998. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | HEB
and
its
subsidiaries
is
a
biopharmaceutical
co.
using
nucleic
acid
technologies
to
develop
therapeutic
products
for
the
treatment
of
viral
diseases
and
certain
cancers.
For
the
six
months
ended
6/30/01,
revenues
decreased
46%
to
$228
thousand.
Net
loss
increased
20%
to
$4.8
million.
Revenues
reflect
decreased
cost
recovery
from
clinical
treatment
programs.
Higher
loss
suffered
from
increased
research
and
development
expenditures. | More
from
Market Guide: Significant
Developments |
| | |
| Position | William Carter, M.D., 62 | Chairman,
Pres, CEO | Robert Peterson, 63 | CFO | Harris Freedman, 65 | VP
for Strategic Alliances | Josephine Dolhancryk, 37 | Treasurer
and Assistant Secretaty | Carol Smith, Ph.D., 48 | Director
of Manufacturing and Process Devel. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|